The new biology: Histopathology

Lancet

Volumn 354, Issue SUPPL.1, 1999, Pages 26-31

  Quirke, Phil ^a   Mapstone, Nic ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RNA; TUMOR MARKER;

BASE MISPAIRING; CANCER; CANCER STAGING; CARCINOGENESIS; CYTOPATHOLOGY; DNA DETERMINATION; DNA REPAIR; FORENSIC PATHOLOGY; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; INFECTION; MEDICAL GENETICS; PREDICTION; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; SEQUENCE ANALYSIS; TUMOR CLASSIFICATION;

EID: 0032789824     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(99)90246-5     Document Type: Article

References (57)

1. Jackson DP, Bell S, Payne J, et al. Extraction and amplification of DNA from archival haematoxylin and eosin sections and cervical cytology Papanicolaou smears. Nucleic Acids Res 1989; 17: 101-34.
2. Jackson DP, Hayden JD, Quirke P. The extraction of nucleic acid from archival material. In: McPherson MJ, Quirke P, Taylor GR, eds. PCR: a practical approach. Oxford: IRL Press, 1991: 29-50.
3. Chung GT, Sunderasan V, Hasleton P, Rudd R, Taylor R, Rabbitts P. Sequential molecular changes in lung cancer development Oncogene 1995; 11: 2591-98.
4. Ogden GR, Hall PA. Field change, clonality and early epithelial cancer: possible lessons from p53. J Pathol 1997; 181: 127-29.
5. Jiang X, Hitchcock A, Bryan EJ, et al. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumour suppressor gene loci. Cancer Res 1996; 56: 3534-39.
6. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinoma. Science 1996; 274: 2057-59.
7. Larson PS, Morenas A, Cupples LA, Huang K, Rosenberg CL. Genetically abnormal clones in histologically normal breast tissue. Am J Pathol 1998; 152: 1591-98.
8. Brentall TA, Crispin DA, Bronner MP, et al. Microsatellite instability in non-neoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 1996; 56: 1237-40.
9. Fozard JBJ, Quirke P, Dixon MF, Giles GR, Bird CC. DNA aneuploidy in ulcerative colitis. Gut 1986; 27: 1414-18.
10. Tamura M, Fukaya T, Murakami T, Uehara S, Yajinia A. Analysis of clonality in human endometriotic cysts based on evaluation of X-chromosome inactivation in archival formalin-fixed, paraffin-embedded tissue. Lab Invest 1988; 78: 213-18.
11. Minamoto T, Yamashita N, Ochiai A, et al. Mutant K-ras in apparently normal mucosa of colorectal cancer patients: its potential as a biomarker of colorectal tumorigenesis. Cancer 1995; 75: 1520-26.
12. Nucci MR, Robinson CR, Longo P, Campbell P, Hamilton SR. Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa. Hum Pathol 1997; 28: 1396-407.
13. Busam KJ, Fletcher CDM. The clinical role of molecular genetics in soft tissue tumor pathology. Cancer Metastasis Rev 1997; 16: 207-27.
14. Mentzel T, Fletcher CD. Recent advances in soft tissue tumor diagnosis. Am J Clin Pathol 1998; 110: 660-70.
15. de Saint Aubain Somerhausen N, Fletcher CD. Soft-tissue sarcomas: an update. Eur J Surg Oncol 1999; 25: 215-20.
16. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
17. Ahuja N, Mohan AL, Li Q, et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997; 57: 3370-74.
18. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870-75.
19. Cawkwell L, Gray S, Murgatroyd H, et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut (in press).
20. Funk D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1-6.
21. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187: 127-37.
22. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
23. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the eficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
24. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Sheidls PG, Harris CC. Molecular epidemiology of human cancer risk; gene-involvement interactions and p53 mutation spectrum in human lung cancer. J Pathol 1999; 187: 8-18.
25. Duncan JA, Reeves JR, Cooke TG. BRCA1 and BRCA2 proteins: roles in health and disease. Mol Pathol 1998; 51: 237-47.
26. Thorson AG, Knezetic JA, Lynch HT. A century of progress in hereditary nonpolypposis colorectal cancer (Lynch syndrome). Dis Colon Rectum 1999; 42: 1-9.
27. Whitehouse A, Meredith DM, Markham AF. DNA mismatch repair genes and their association with colorectal cancer. Int J Mol Med 1998; 1: 469-74.
28. Lu SL, Kawabata M, Imamura T, et al. HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nat Genet 1998; 19: 17-8.
29. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997; 17: 79-83.
30. Perera FP. Environment and cancer: who are susceptible? Science 1997; 278: 1068-73.
31. Marshall E. Drug firms to create public database of genetic mutations. Science 1999; 284: 406-07.
32. Negrin RS. Minimal residual disease. Curr Opin Hematol 1998; 5: 488-93.
33. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332: 429-35.
34. Kodera Y, Nakanishi H, Yamamura Y, et al. Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int J Cancer 1998; 79: 429-33.
35. Yamamoto N, Kato Y, Yanagisawa A, Ohta H, Takahashi T, Kitagawa T. Predictive value of genetic diagnosis for cancer micrometastasis: histologic and experimental appraisal. Cancer 1997; 80: 1393-98.
36. Brenner TL, Adams VR. First MAb approved for treatment of metastatic breast cancer. J Am Pharmaceut Assoc 1999; 39: 236-38.
37. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-28.
38. Ferry DR. Testing the role of P-glycoprotein expression in clinical trials: applying pharmacological principles and best methods for detection together with good clinical trials methodology. Int J Clin Pharmacol Ther 1998; 36: 29-40.
39. Barratt P, Seymour MT, Stenning S, Birbeck KF, Quirke P, and the AXIS collaborators. Molecular markers to predict survival and benefit from adjuvant intraportal 5FU in colon cancer. 1999 Annual Meeting of the American Society of Clinical Oncology, Atlanta, USA (abstr 1030).
40. Muller C, Petermann D, Stain C, et al. Whipple's disease: comparison of histology with diagnosis based on polymerase chain reaction in four consecutive cases. Gut 1997; 40: 425-27.
41. Foy CA, Quirke P, Lewis FA, Futers TS, Bodansky HJ. A search for candidate viruses in type 1 diabetic pancreas using the polymerase chain reaction. Diabet Med 1994; 11: 564-69.
42. Belgrader P, Benett W, Hadley D, et al. PCR detection of bacteria in seven minutes. Science 1999; 284: 449-50.
43. Rodman DM, Zamudio S. The cystic fibrosis heterozygote - advantage in surviving cholera? Med Hypoth 1991; 36: 253-58.
44. Ikeda M, Yu DT. The pathogenesis of HLA-B27 arthritis: role of HLA-B27 in bacterial defense. Am J Med Sci 1998; 316: 257-63.
45. Roger M. Influence of host genes on HIV-1 disease progression. FASEB J 1998; 12: 625-32.
46. Hurme M, Lahdenpohja N, Santtila S. Gene polymorphisms of interieukins 1 and 10 in infectious and autoimmune diseases. Ann Med 1998; 30: 469-73.
47. Handyside AH, Lesko JG, Tarin JJ, Winston RM, Hughes MR. Birth of a normal girl after in vitro fertilization and preimplantation diagnostic testing for cystic fibrosis. N Engl J Med 1992; 327: 905-09.
48. Findlay I, Frazier R, Taylor A, Quirke P, Urquhart A. Single cell DNA fingerprinting for forensic applications. Nature 1997; 389: 355-56.
49. Wells D, Sherlock JK, Handyside AH, Delhanty JD. Detailed chromosomal and molecular genetic analysis of single cells by whole genome amplification and comparative genomic hybridisation. Nucleic Acids Res 1999; 27: 1214-18.
50. Boyle JO, Mao L, Brennan JA, et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 1994; 168: 429-32.
51. Xu X, Stower MJ, Reid IN, Garner RC, Burns PA. Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. Clin Cancer Res 1996; 2: 1795-800.
52. Mao L. Genetic alterations as clonal markers for bladder cancer detection in urine. J Cell Biochem Suppl 1996; 25: 191-96.
53. Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999; 229: 101-08.
54. Debouck C, Goodfellow PN. DNA microarrays in drug discovery and development. Nat Genet 1999; 21: 48-50.
55. Iyer VR, Eisen MB, Ross DT, et al. The transcriptional program in the response of human fibroblasts to serum. Science 1999; 283: 83-87.
56. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome microarrays. Science 1999; 284: 1520-23.
57. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-47.